Advertisement
Advertisement
U.S. markets open in 8 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.06-0.22 (-1.95%)
At close: 04:00PM EST
11.69 +0.63 (+5.70%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.28
Open11.39
Bid0.00 x 1000
Ask0.00 x 3100
Day's Range10.98 - 11.70
52 Week Range3.83 - 23.49
Volume1,345,556
Avg. Volume2,313,254
Market Cap543.7M
Beta (5Y Monthly)0.40
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Altimmune, Inc.
    EBS: Lowering target price to $9.00EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Altimmune to Participate at Two Upcoming Investor Conferences

    GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences: Evercore ISI 5th Annual HealthCONx Virtual ConferenceTuesday, November 29, 2022Fireside chat at 10:55 am Eastern Time Piper Sandler 34th Annual Healthcare Conference in New York, NYThursday, December 1, 2022Fireside chat at 10:00 am Eastern Time The sess

  • GlobeNewswire

    Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update

    Topline 24-week data from Phase 1b trial in subjects with non-alcoholic fatty liver disease (NAFLD) expected mid-December 2022 Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected Q1 2023 GAITHERSBURG, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2022, and provided a business update. “We continue on course in our advancement of p

  • GlobeNewswire

    Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10

    GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on November 10 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at ht

Advertisement
Advertisement